---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-269514"
form_type: "8-K"
ticker: null
cik: "0001445499"
company_name: "IMPEL PHARMACEUTICALS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:54:47.427714+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Impel Pharmaceuticals CEO Adrian Adams resigns; CCO Len Paolillo named interim CEO

## Summary
- Adrian Adams resigned as Chairman, President and CEO effective Nov. 4, 2023; no disagreement cited.
- Leonard S. Paolillo, current Chief Commercial Officer, appointed Interim President and CEO.
- Paolillo joined Impel in March 2021; previously EVP & CCO at Kyowa Kirin North America.
- Board to formally appoint Paolillo upon Adams's departure.

## SEC filing metadata
- accession: 0001193125-23-269514
- form_type: 8-K
- cik: 0001445499
- company_name: IMPEL PHARMACEUTICALS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445499/000119312523269514/0001193125-23-269514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445499/000119312523269514/d397416d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-269514
- JSON: https://secwatch.observer/filing/0001193125-23-269514.json
- Plain text: https://secwatch.observer/filing/0001193125-23-269514.txt

## Key facts
- Executive change
  Adrian Adams resigned as Chairman of the Board, President and Chief Executive Officer at IMPEL PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Chairman of the Board, President and Chief Executive Officer
  source text: On October 29, 2023, Adrian Adams gave notice of his resignation from his position as Chairman of the Board and as President and Chief Executive Officer of Impel Pharmaceuticals Inc. (the “ Company ”) effective November 4, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445499/000119312523269514/0001193125-23-269514-index.htm
- Executive change
  Leonard S. Paolillo was appointed as Interim President and Chief Executive Officer at IMPEL PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: The Board of Directors of the Company intends to appoint Leonard S. Paolillo as Interim President and Chief Executive Officer effective upon Mr. Adams’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445499/000119312523269514/0001193125-23-269514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.